

## REMARKS

### **Response to Restriction Requirement**

Claims 1-83 are currently pending in this application. In the Official Action mailed December 14, 2005, a restriction requirement was entered requiring Applicants to elect a single invention from the following groups of claims:

Group I, Claims 1-3, 5, 14-19, 21, 30-32, 34, 43-45, 47, 56-58, 60, 69-71, 73, 82, and 83, drawn to triazine compounds and compositions;

Group II, Claims 4, 20, 33, 46, 59, and 72, drawn to a composition of the triazine compounds of Group I containing therapeutic agents, receptors, etc.;

Group III, Claims 12, 13, 28, 29, 41, 42, 54, 55, 67, 68, 80, and 81, drawn to multiple methods of use of the triazine compounds of Group I;

Group IV, Claims 6-8, 22-24, 35-37, 48-50, 61-63, and 74-76, drawn to a medical device containing a composition of the triazine compounds of Group I;

Group V, Claims 9, 10, 25, 26, 38, 39, 51, 52, 64, 65, 77, and 78, drawn to a microarray; and

Group VI, Claims 11, 27, 40, 53, 66, and 79, drawn to an expression profile database.

In response to the restriction requirement, Applicants hereby elect Group I, Claims 1-3, 5, 14-19, 21, 30-32, 34, 43-45, 47, 56-58, 60, 69-71, 73, 82, and 83.

### **Election of Species Requirement**

In the Official Action mailed December 14, 2005, an election of species requirement was also entered requiring Applicants to elect a single species among those recited in Claim 82. Applicants hereby elect the species 4-{4-[4-(3-chloro-4-methoxy-phenylamino)-6-cycloheptylamino-[1,3,5]triazin-2-yloxy]-phenyl}-2-methyl-but-3-yn-2-ol.

In further response to the Election/Restriction Requirement mailed December 14, 2005, Applicants provide the following elected claims that read on the elected species are Claims 1-3, 5, 69-71, 73, 82, and 83.

## CONCLUSION

The foregoing is submitted as a full and complete Response to the Restriction Requirement mailed December 14, 2005. Early and favorable consideration is earnestly solicited.

If the Examiner believes any informalities remain in the application that can be resolved by telephone interview, a telephone call to the undersigned attorney is requested.

No fees are believed due, however, the Commissioner is hereby authorized to charge any deficiencies which may be required, or credit any overpayment, to Deposit Account Number 09-0528.

Respectfully submitted,



David E. Wigley, Ph.D.  
Reg. No. 52,362

WOMBLE CARLYLE SANDRIDGE & RICE, PLLC  
P.O. Box 7037  
Atlanta, GA 30357-0037  
(404) 879-2435 (Telephone)  
(404) 879-2935 (Facsimile)  
(404) 872-7000 (Firm)

Our Docket No. R18631 1090.1.0 (51880.0051.5)  
Client Ref. No. 18631-0157